These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 32819369)

  • 21. [DIRA: life-threatening but treatable inherited inflammatory disease].
    ter Haar NM; van Royen A; van Gijn ME; Frenkel J
    Ned Tijdschr Geneeskd; 2010; 154():A1601. PubMed ID: 20482912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Deficiency of Interleukin-1 Receptor Antagonist: A Case with Late Onset Severe Inflammatory Arthritis, Nail Psoriasis with Onychomycosis and Well Responsive to Adalimumab Therapy.
    Kutukculer N; Puel A; Eren Akarcan S; Moriya K; Edeer Karaca N; Migaud M; Casanova JL; Aksu G
    Case Reports Immunol; 2019; 2019():1902817. PubMed ID: 31467740
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of IL1RN Variants on Response to Interleukin-1 Blocking Therapy in Systemic Juvenile Idiopathic Arthritis.
    Hinze C; Fuehner S; Kessel C; Wittkowski H; Lainka E; Baehr M; Hügle B; Haas JP; Ganser G; Weißbarth-Riedel E; Jansson A; Foell D
    Arthritis Rheumatol; 2020 Mar; 72(3):499-505. PubMed ID: 31599092
    [TBL] [Abstract][Full Text] [Related]  

  • 24. DIRA, DITRA, and new insights into pathways of skin inflammation: what's in a name?
    Cowen EW; Goldbach-Mansky R
    Arch Dermatol; 2012 Mar; 148(3):381-4. PubMed ID: 22431779
    [No Abstract]   [Full Text] [Related]  

  • 25. PAPA Syndrome: Challenges in Achieving Long-Term Remission.
    Smajlović H; Prohić A
    Acta Dermatovenerol Croat; 2023 Nov; 31(2):106-109. PubMed ID: 38006373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases.
    Bettiol A; Lopalco G; Emmi G; Cantarini L; Urban ML; Vitale A; Denora N; Lopalco A; Cutrignelli A; Lopedota A; Venerito V; Fornaro M; Vannacci A; Rigante D; Cimaz R; Iannone F
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999610
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of subcutaneous tocilizumab in a patient with severe gout refractory to anakinra.
    Calvo-Aranda E; Sanchez-Aranda FM
    Rheumatology (Oxford); 2021 Nov; 60(11):e375-e377. PubMed ID: 34009241
    [No Abstract]   [Full Text] [Related]  

  • 28. Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry.
    Sota J; Rigante D; Cimaz R; Cattalini M; Frassi M; Manna R; Sicignano LL; Verrecchia E; Aragona E; Maggio MC; Lopalco G; Emmi G; Parronchi P; Cauli A; Wiesik-Szewczyk E; Hernández-Rodríguez J; Gaggiano C; Tarsia M; Mourabi M; Ragab G; Vitale A; Fabiani C; Frediani B; Lamacchia V; Renieri A; Cantarini L;
    Rheumatology (Oxford); 2021 Dec; 60(12):5705-5712. PubMed ID: 33961014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS, TRAPS, MKD, and DIRA).
    Cetin Gedik K; Arici ZS; Kul Cinar O; Garcia-Bournissen F; Romano M; Demirkaya E
    Paediatr Drugs; 2024 Mar; 26(2):113-126. PubMed ID: 38376736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist.
    Romano M; Arici ZS; Piskin D; Alehashemi S; Aletaha D; Barron KS; Benseler S; Berard R; Broderick L; Dedeoglu F; Diebold M; Durrant KL; Ferguson P; Foell D; Hausmann J; Jones OY; Kastner DL; Lachmann HJ; Laxer RM; Rivera D; Ruperto N; Simon A; Twilt M; Frenkel J; Hoffman H; de Jesus AA; Kuemmerle-Deschner JB; Ozen S; Gattorno M; Goldbach-Mansky R; Demirkaya E
    Ann Rheum Dis; 2022 Jul; 81(7):907-921. PubMed ID: 35623638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist.
    Romano M; Arici ZS; Piskin D; Alehashemi S; Aletaha D; Barron K; Benseler S; Berard RA; Broderick L; Dedeoglu F; Diebold M; Durrant K; Ferguson P; Foell D; Hausmann JS; Jones OY; Kastner D; Lachmann HJ; Laxer RM; Rivera D; Ruperto N; Simon A; Twilt M; Frenkel J; Hoffman HM; de Jesus AA; Kuemmerle-Deschner JB; Ozen S; Gattorno M; Goldbach-Mansky R; Demirkaya E
    Arthritis Rheumatol; 2022 Jul; 74(7):1102-1121. PubMed ID: 35621220
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The challenge of autoinflammatory syndromes: with an emphasis on hyper-IgD syndrome.
    van der Meer JW; Simon A
    Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii23-ii29. PubMed ID: 27856657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel mutation in the interleukin-1 receptor antagonist associated with intrauterine disease onset.
    Altiok E; Aksoy F; Perk Y; Taylan F; Kim PW; Ilıkkan B; Asal GT; Goldbach-Mansky R; Sanal O
    Clin Immunol; 2012 Oct; 145(1):77-81. PubMed ID: 22940634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever.
    Şahin A; Derin ME; Albayrak F; Karakaş B; Karagöz Y
    Adv Rheumatol; 2020 Jan; 60(1):12. PubMed ID: 32000860
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunological repertoire linked to PSTPIP1-associated myeloid-related inflammatory (PAMI) syndrome.
    Mendonça LO; Terreri MT; Osaku FM; Barros SF; Köhler KF; Prado AI; Barros MT; Kalil J; Castro FFM
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):126. PubMed ID: 34399798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inflammasome and cytokine blocking strategies in autoinflammatory disorders.
    Moll M; Kuemmerle-Deschner JB
    Clin Immunol; 2013 Jun; 147(3):242-75. PubMed ID: 23697917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chronic cutaneous pustulosis due to a 175-kb deletion on chromosome 2q13: excellent response to anakinra.
    Brau-Javier CN; Gonzales-Chavez J; Toro JR
    Arch Dermatol; 2012 Mar; 148(3):301-4. PubMed ID: 22431772
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens.
    Kuemmerle-Deschner JB; Wittkowski H; Tyrrell PN; Koetter I; Lohse P; Ummenhofer K; Reess F; Hansmann S; Koitschev A; Deuter C; Bialkowski A; Foell D; Benseler SM
    Arthritis Res Ther; 2013; 15(3):R64. PubMed ID: 23718630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic recurrent multifocal osteomyelitis and deficiency of interleukin-1-receptor antagonist.
    Sakran W; Shalev SA; Sakran W; Shalev SA; El-Shanti H; Uziel Y; Uziel Y
    Pediatr Infect Dis J; 2013 Jan; 32(1):94. PubMed ID: 23241992
    [No Abstract]   [Full Text] [Related]  

  • 40. [The role of interleukin-1 and interleukin-1-receptor antagonist in development of familial mediterranean fever and other autoinflammatory diseases].
    Dzhidoian Z
    Georgian Med News; 2011 May; (194):53-6. PubMed ID: 21685523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.